This report analyzes the worldwide markets for Nanobiotechnology in US$ Million by the following technology segments: Nanomaterials (Solid Inorganic Nanoparticles, Nanocomposites, Nanostructured Materials & Membranes, Nanotubes and Fullerenes, & Other Nanomaterials), and Nanodevices/Tools. The report provides separate comprehensive analytics for the US, Japan, Europe, and Rest of World. Annual forecasts are provided for each region for the period of 2007 through 2015. Also, a six-year historic analysis is provided for these markets. The report profiles 140 companies including many key and niche players worldwide such as Aduro BioTech, Abraxis Bioscience, Inc., Arrowhead Research Corporation, Calando Pharmaceuticals, Inc., Unidym, Inc., Agilent Technologies Inc., Asklepios BioPharmaceutical Inc., Biosante Phosphate Pharmaceuticals, Inc., Elan Pharmaceuticals, Flamel Technologies, Inc., Gilead Sciences Inc., Life Technologies Corporation, BioTrove, Inc., Invitrogen Corporation, NanoBio Corporation, Nanogen, Inc., Nanophase Technologies Corporation, pSivida Ltd., Sigma Aldrich Company, Starpharma Holdings Ltd., Dendritic Nanotechnologies, Inc., SkyePharma Pharmaceuticals, and Zyvex Instruments LLC. Market data and analytics are derived from primary and secondary research. Company profiles are mostly extracted from URL research and reported select online sources. 

TABLE OF CONTENTS 

NANOBIOTECHNOLOGY		MCP-1476
A GLOBAL STRATEGIC BUSINESS REPORT


                                       CONTENTS 



  I. INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONS

      Study Reliability and Reporting Limitations                       I-1
      Disclaimers                                                       I-2
      Data Interpretation & Reporting Level                             I-3
       Quantitative Techniques & Analytics                              I-3
      Product Definitions and Scope Of Study                            I-3
      1. Nanomaterials                                                  I-4
       Solid Inorganic Nanoparticles                                    I-4
       Nanocomposites                                                   I-4
       Nanostructured Materials and Membranes                           I-4
       Nanotubes and Fullerenes                                         I-4
       Other Nanomaterials                                              I-4
        Nanoshells                                                      I-4
        Nanohorns                                                       I-5
        Nanocapsules                                                    I-5
      2. Nanodevices/Tools                                              I-5


  II. EXECUTIVE SUMMARY

  1. INDUSTRY OVERVIEW                                                  II-1
      A Curtain Raiser                                                  II-1
      Nanobiotechnology - The Next Big Thing                            II-2
       Nanotechnology & Biology Tie the Knot: “Two to Tango”            II-3
       Where Conventional Molecular Science Falls Short Nanobio
        Steps In                                                        II-4
       What's The Obsession With Size?                                  II-4
       Why Analysis at the Cellular Level is Important?                 II-5
       Lessons from Nature                                              II-5
      Dawn Breaks On Nanobiotechnology                                  II-6
       Table 1: Nanobiotechnology and Related Medical Applications
       Market (2007): Percentage Share Breakdown of Activity
       Distribution by Region and Organizational Set-Up (includes
       corresponding Graph/Chart)                                       II-7

       Table 2: Percentage Breakdown of Number of Nanotechnology
       Companies in Healthcare Industry Worldwide by Region/ Country
       (2008) (includes corresponding Graph/Chart)                      II-7

       Table 3: Percentage Breakdown of Number of Nanotechnology
       Companies in Healthcare Industry Worldwide by Type - Private
       and Public Sector (2008)                                         II-7

       Table 4: Percentage Breakdown of Number of Nanotechnology
       Companies in Healthcare Industry Worldwide By Sector -
       Therapeutics and Drug Delivery; Clinical Diagnostics; Drug
       Discovery Tools and Biomedical Research; and Biomaterials and
       Biomedical Implants (2008) (includes corresponding
       Graph/Chart)                                                     II-8

       Table 5: Percentage Breakdown of Number of Nanotechnology
       Companies in The field of Therapeutics and Drug Delivery
       Worldwide by Area - Targeted Nanoparticles, Solubility &
       Reformulation, Sustained Release, Blood Brain Barrier,
       Nanomaterial Therapeutics and Others (2008) (includes
       corresponding Graph/Chart)                                       II-8

       Table 6: Percentage Breakdown of Number of Nanotechnology
       Companies in the field Therapeutics Worldwide by Therapeutic
       Area - Oncology, Infectious Diseases, Central Nervous System
       Diseases, Nutraceuticals, Ophthalmology and Others (2008)
       (includes corresponding Graph/Chart)                             II-8

       Table 7: Percentage Breakdown of Number of Nanotechnology
       Companies in the field of Clinical Imaging and Diagnostics
       Worldwide by Area - Tags and Probes; Imaging Agents;
       Biosensors and Bio-detection; and Instruments (2008)
       (includes corresponding Graph/Chart)                             II-9
      Demystifying the Intriguing World of Nanobiotech                  II-9
       A Meeting Place of Medicine's Best Solutions                     II-9
       Nanobiotechnology Promises to Deliver Nanomedicine               II-11
       Nanobiotechnology to Become Viable for All Drug Development
        Stages                                                          II-12
        Nanobioproducts in R&D As of 2007 & 2008                        II-12
        List of Marketed Nanoparticle-Based Pharmaceutical Products
         As of the Year 2007                                            II-13
       Nanoparticles: The Foundation of Nanobiotechnology               II-13
       Improved Optical Properties and Stability of Nanoparticles       II-14
       Nanoemulsions                                                    II-14
       Diagnosis & Treatment of Cancer                                  II-15
       Challenges                                                       II-15
        Commercial Exploration: A Treacherous Voyage                    II-16
        Conventional Medicine to Contest Nanomedicine Adoption          II-17
        Nanomaterials Use: Weighed Down with Toxicity Concerns          II-17
        Production Issues Continue to Plague Nanobiotech Industry       II-18
        Lack of De Facto Standards: A Challenge to Reckon With          II-19
      The Promise of Nanobiotechnology                                  II-19
       Biological Weaponries Against Diseases Come in Small Packages    II-19
       Proffered Benefits of Nanobiotechnology                          II-20
       Opportunity & Beyond                                             II-21
      Nanobiotechnology - Will it Live Up to the Expectations?          II-21
      The Future of Nanobiotechnology: Shape of Things to Come          II-22
       Nanobiotechnology: The Outer Limits                              II-22
       Futuristics: A Rumination                                        II-23
       Nanobiotechnology In the Year 2015                               II-23
        Field of Nanodiagnostics                                        II-23
        Field of Regenerative Medicine                                  II-24
        Field of Targeted Drug Delivery                                 II-24
       Conclusions                                                      II-24

  2. MARKET DYNAMICS                                                    II-25
      Nanotechnology in the Current Economic Climate: A Review          II-25
      Nanobio Feels the Pinch or Does It ?: A Closer Look               II-25
       Table 8: Global Nanobiotechnology Market (2007): Percentage
       Share Breakdown of Investments by Region (includes
       corresponding Graph/Chart)                                       II-26
      Government Funding of Nanotechnology Slows Down                   II-26
       Table 9: Worldwide Government Funding in Nanotechnology
       (2008-2015) (In US$ Billion) (includes corresponding
       Graph/Chart)                                                     II-26
       Developing Countries to Rise Over the Horizon                    II-27
       Table 10: Worldwide Funding in Nanotechnology (2004 & 2009):
       Percentage Breakdown of Value Investments by Country/Region:
       A Comparison  (includes corresponding Graph/Chart)               II-27
      Consolidation Sharpens the Industry's Edge                        II-28
      Demand for Novel Products to Push Up Growth                       II-28
      The Regulatory Framework Evolves with the Technology              II-28
      Nanomaterials & Nanoparticles Witness Robust Activity             II-28
      Quantum Dot Patents Pose Legal Tangles                            II-29
      Miniaturized Liquid Handling Becomes Progressive                  II-29
      Trends in Nanotechnology Enabled Drug Delivery Systems            II-30
      Robust Growth On Cards                                            II-30
       Table 11: Global Nanotechnology-Enabled Drug Delivery Systems
       Market (2015 (P)): Percentage Share Breakdown of
       Nanoparticles, Dendrimers, Polymer Therapeutics and Other
       Nanostructures (includes corresponding Graph/Chart)              II-30
      Patent Expiries: A Key Driver                                     II-31
      Nanotechnology Enabled Drug Delivery to Exhume Unused Drugs       II-31

  3. INDUSTRY ISSUES                                                    II-32
      Embroilment Over Ethical Issues                                   II-32
      Social Relevance                                                  II-32
      Economic Relevance                                                II-34

  4. INDUSTRY STRUCTURE                                                 II-35
      Industry Structure: A Quick Primer                                II-35
       A Dissection of Select Segments                                  II-35
        Nanoparticles                                                   II-35
        Nanotubes and Fullerenes                                        II-36
        Dendrimers                                                      II-36
      A Peek Into the Regulatory Framework                              II-36
       United States                                                    II-37
       Europe                                                           II-37
        A Closer Look at Regional Nano Efforts                          II-37
         United States: Unraveling the Country's Edge                   II-37
          Table 12: Global Intellectual Property Rights in
           Nanotechnology By Leading Countries (2007)                   II-38
         Europe: Hot On the Heels of the US                             II-38
          Germany                                                       II-39
          France                                                        II-39
          United Kingdom                                                II-39
          Scandinavia                                                   II-39
          Japan: A Noteworthy Region                                    II-40

  5. NANOBIO'S EPOCHAL STRIDES IN MODERN MEDICINE                       II-41
      A Primer                                                          II-41
      Impact on Drug Delivery Systems                                   II-41
       Benefits Offered                                                 II-43
        Drug Encapsulation                                              II-43
        High Level of Specificity                                       II-43
        Increase in Drug Solubility and Uptake                          II-43
        Greater Usage Flexibility                                       II-44
      Impact On Molecular Diagnostic Imaging                            II-44
       Seeing The Unseen                                                II-44
      Impact On Pharmaceutical Drug Formulations                        II-45
      Impact On Therapeutics                                            II-46
       Silver Nanoparticles as Effective Antimicrobial Agents           II-46
      Modern Day Nanomedicine: A Current Scenario                       II-47
       Nanomedicine: The Cynosure of All Eyes                           II-47
        Drug Delivery Systems Epitomized by Nanomedicine                II-48
         Targeted NanoDrug Delivery & Release                           II-48
          Active and Passive Targeting Mechanisms in Drug Delivery      II-49
          Sustained and Pulsatile Release Mechanisms in Drug Delivery   II-49
         A Peek Into Potential Nanobio Enabled Drug Carriers            II-49
          Micelles:                                                     II-50
          Liposomes:                                                    II-50
          Dendrimers & Liquid Crystals:                                 II-50
          Nanoparticles:                                                II-50
          Polymeric Nanoparticles:                                      II-51
          Hydrogels:                                                    II-51
          Molecularly Imprinted Polymers:                               II-51
          Microelectromechanical Systems (MEMS):                        II-51
          Nanosuspensions:                                              II-52
         Fullerenes: A Platform for GenX Drug Delivery                  II-52
          Types of Nano-Based Drug Delivery Systems, Related
           Materials, and Structures                                    II-53
        Dynamics of Regenerative Medicine                               II-53
         Tissue Engineering and Restorations                            II-54
       Nanotechnology Enabled Diagnostics                               II-55
        Promised Path Breaking Applications in Molecular Diagnostics & 
         Imaging                                                        II-55
         In-Vitro Diagnostics                                           II-56
         In-Vivo Diagnostics                                            II-57
          Nanoprobes & Implantable Devices in In-vivo Imaging           II-57
         Nanocomposites in Molecular Labeling & Diagnostics             II-58
         Laboratory-on-a-Chip - A Revolutionary Technology in
          Biomolecular Detection                                        II-58
         Biosensors - Heralding New Opportunities in Molecular
          Diagnostics                                                   II-59
          Nanobiosensors - A New Approach to Diagnostics Testing        II-59
          Despite Huge Potential   Key Hurdles Remain in
           Commercialization                                            II-60
         Magnetic Nanoparticles for Imaging Applications in MRI         II-60
         Dendrimers Promise Milestone Applications in MRI               II-60
       Conclusions                                                      II-61
      Gauging the Real World Impact of Nanobiotech on Cancer: A Case
       Study                                                            II-61
       Quantum Dots Cock a Snook at Traditional Anti-Body Labeling
        Agents                                                          II-62
       Chemotherapeutic Reengineering & Gene Therapy: New Treatment
        Regimes                                                         II-63
       Laboratory-on-chip (LOC): A Platform for Cancer Diagnosis        II-63

  6. TECHNOLOGY OVERVIEW                                                II-64
      Nanotechnology: An Introduction                                   II-64
       A Revolution in the Making                                       II-64
      Nanobiotechnology: An Exposition                                  II-65
      Nanobiotechnology & Medicine                                      II-65
      Nanobiotechnology & Biofuels                                      II-66
       Global Nanobiotechnology Market (2005): Major Products           II-66
       Global Nanobiotechnology Market (2005): Major Products Under
        Development                                                     II-66
      Analysis of Major Technology Segments                             II-67
       Nanomaterials                                                    II-67
        Nanoparticles                                                   II-68
         Nanoparticles in Labeling or Bio Tagging                       II-68
         Nanoparticles as Biomarkers                                    II-69
         Classification of Nanoparticles                                II-69
          Solid Nanoparticles                                           II-69
          Solid Lipid Nanoparticles                                     II-69
          Calcium Phosphate Nanoparticles                               II-69
          Dendrimers                                                    II-70
           Dendrimers as Templates for Synthesis of Hybrid
            Nanostructures                                              II-70
        Nanocomposites                                                  II-70
         Lamellar Nanocomposites                                        II-71
        Nanostructured Materials and Membranes                          II-71
        Nanotubes and Fullerenes                                        II-71
        Other Nanomaterials                                             II-72
         Nanoshells                                                     II-72
         Nanohorns                                                      II-72
         Nanocapsules                                                   II-72
      Nanodevices                                                       II-73
      Nanotools                                                         II-73
       Select Nanotools                                                 II-73
        Atomic Force Microscopes                                        II-73
        Hot Embossing Lithography                                       II-74
        Dip-Pen Nanolithography                                         II-74

  7. GLOBAL RESEARCH CENTERS AND INSTITUTIONS                           II-75
      Centre for Biologic Nanotechnology (USA)                          II-75
      Centre for Biological and Environmental Nanotechnology (USA)      II-75
      Institute of Bioengineering and Nanotechnology (Singapore)        II-75
      The Nanobiotechnology Center (USA)                                II-76
      The Tyndall National Institute (Ireland)                          II-76

  8. RECENT INDUSTRY ACTIVITY/PRODUCT LAUNCHES                          II-77
      GSK Inks License With NanoBio to Market NB-001                    II-77
      CPN Establishes New Medical Nanobiotechnology R&D Center          II-77
      IBM to Setup New Research Center in Wroclaw                       II-77
      Life Technologies and Zymera Ink Licensing Deal for Quantum
       Dots Technology                                                  II-77
      APR Acquires Nanotechnology Platform Technology for Preparing
       Biotechnology Products                                           II-78
      Lockheed Teams Up with IIT-Delhi for Nanobiotechnology Research   II-78
      Piedmont Triad to Institute Statewide Nanobiotech Center          II-78
      Biocon and Abraxis Introduce ABRAXANE in India                    II-79
      Starpharma Launches a Research Reagent Kit                        II-79
      Monash Enters Into a Deal with National Fabrication Facility
       of Australia                                                     II-80
      Taiwan Inks Nanotechnology Collaboration Deal with Australia      II-80
      Avanti Institutes New Targeted Drug Delivery Company, Chikujee
       Therapeutics                                                     II-81
      CytoViva Rolls Out New Research Tool for Nanotechnology           II-81
      Dabur Obtains DCGI Approval for Nanoxel in New Indications        II-81
      Researchers Discover New Nanoparticles for Treating Brain
       Infection                                                        II-81
      Capsulution Tests Nanoparticle-Based Drug Formulation for
       Improved Bio-Availability                                        II-82
      Invitrogen Signs Agreement with Genisphere                        II-82
      Sigma-Aldrich Signs Deal With Nanoco Technologies                 II-83
      Unidym Sells First License Option for Patent Portfolio to MDA     II-83
      Unidym Spins Off Carbon Nanotubes Therapeutics Business into
       Ensysce Biosciences                                              II-84
      Nacalai USA and Nano-C Enter into Collaboration Agreement for
       HPLC Technology                                                  II-84
      Advanced Materials Technology Obtains License for LBL(R)
       Technology from Capsulution                                      II-84
      Nanogen and The Elitech Group Announce Merger                     II-84
      NanoViricides Signs MCRADA Agreement with CDC for Rabies          II-85
      Manhattan Scientifics Acquires Metallicum                         II-85
      HemCon Medical Technologies Acquires Alltracel Pharmaceuticals    II-85
      CN Probes Inks Agreement With a Leading MEMS Foundry              II-86
      PrimeGen Biotech LLC Enters into Corporate Alliance with Unidym   II-86
      Ondine Acquires Exclusive License from UCL Business               II-86
      Dabur Introduces Nanotechnology Based Anti-Cancer Drug
       Delivery System - Nanoxel                                        II-87
      Mitsui Ties Up With NIOSH to Evaluate Safety of Carbon Nanotubes  II-87
      Unidym Merges with Carbon Nanotechnologies                        II-87

  9. FOCUS ON SELECT GLOBAL PLAYERS                                     II-89
      Aduro BioTech (USA)                                               II-89
      Abraxis Bioscience, Inc (USA)                                     II-89
      Arrowhead Research Corporation (USA)                              II-89
       Calando Pharmaceuticals, Inc. (USA)                              II-90
       Unidym, Inc. (USA)                                               II-90
      Agilent Technologies Inc (USA)                                    II-90
      Asklepios BioPharmaceutical Inc (USA)                             II-91
      Biosante Phosphate Pharmaceuticals, Inc. (USA)                    II-91
      Elan Pharmaceuticals (USA)                                        II-91
      Flamel Technologies, Inc. (France)                                II-91
      Gilead Sciences Inc (USA)                                         II-92
      Life Technologies Corporation (USA)                               II-92
       BioTrove, Inc. (USA)                                             II-92
       Invitrogen Corporation (USA)                                     II-92
      NanoBio Corporation (USA)                                         II-93
      Nanogen, Inc. (US)                                                II-93
      Nanophase Technologies Corporation (USA)                          II-94
      pSivida Ltd (Australia)                                           II-94
      Sigma Aldrich Company (USA)                                       II-94
      Starpharma Holdings Ltd. (Australia)                              II-95
       Dendritic Nanotechnologies, Inc. (USA)                           II-95
      SkyePharma Pharmaceuticals (UK)                                   II-95
      Zyvex Instruments LLC (USA)                                       II-96

  10. GLOBAL MARKET PERSPECTIVE                                         II-97
      Table 13: World Recent Past, Current & Future Analysis for
      Nanobiotechnology by Geographic Region - USA, Japan, Europe,
      and Rest of World Markets Independently Analyzed with Annual
      Revenue Figures in US$ Million for Years 2007 through 2015
      (includes corresponding Graph/Chart)                              II-97

      Table 14: World Historic Review for Nanobiotechnology by
      Geographic Region - USA, Japan, Europe, and Rest of World
      Markets Independently Analyzed with Annual Revenue Figures in
      US$ Million for Years 2001 through 2006 (includes
      corresponding Graph/Chart)                                        II-98

      Table 15: World 13-Year Perspective for Nanobiotechnology by
      Geographic Region - Percentage Breakdown of Revenues for USA,
      Japan, Europe, and Rest of World for Years 2003, 2009 & 2015
      (includes corresponding Graph/Chart)                              II-99
      Analytics by Product Segment                                      II-100
      Table 16: World Recent Past, Current & Future Analysis for
      Nanomaterials by Geographic Region - USA, Japan, Europe, and
      Rest of World Markets Independently Analyzed with Annual
      Revenue Figures in US$ Million for Years 2007 through 2015
      (includes corresponding Graph/Chart)                              II-100

      Table 17: World Historic Review for Nanomaterials by
      Geographic Region - USA, Japan, Europe, and Rest of World
      Markets Independently Analyzed with Annual Revenue Figures in
      US$ Million for Years 2001 through 2006 (includes
      corresponding Graph/Chart)                                        II-101

      Table 18: World 13-Year Perspective for Nanomaterials by
      Geographic Region - Percentage Breakdown of Revenues for USA,
      Japan, Europe, and Rest of World for Years 2003, 2009 & 2015
      (includes corresponding Graph/Chart)                              II-102

      Table 19: World Recent Past, Current & Future Analysis for
      Solid Inorganic Nanoparticles by Geographic Region - USA,
      Japan, Europe, and Rest of World Markets Independently
      Analyzed with Annual Revenue Figures in US$ Million for Years
      2007 through 2015 (includes corresponding Graph/Chart)            II-103

      Table 20: World Historic Review for Solid Inorganic
      Nanoparticles by Geographic Region - USA, Japan, Europe, and
      Rest of World Markets Independently Analyzed with Annual
      Revenue Figures in US$ Million for Years 2001 through 2006
      (includes corresponding Graph/Chart)                              II-104

      Table 21: World 13-Year Perspective for Solid Inorganic
      Nanoparticles by Geographic Region - Percentage Breakdown  of
      Revenues for USA, Japan, Europe, and Rest of World for Years
      2003, 2009 & 2015 (includes corresponding Graph/Chart)            II-105

      Table 22: World Recent Past, Current & Future Analysis for
      Nanocomposites by Geographic Region - USA, Japan, Europe, and
      Rest of World Markets Independently Analyzed with Annual
      Revenue Figures in US$ Million for Years 2007 through 2015
      (includes corresponding Graph/Chart)                              II-106

      Table 23: World Historic Review for Nanocomposites by
      Geographic Region - USA, Japan, Europe, and Rest of World
      Markets Independently Analyzed with Annual Revenue Figures in
      US$ Million for Years 2001 through 2006  (includes
      corresponding Graph/Chart)                                        II-107

      Table 24: World 13-Year Perspective for Nanocomposites by
      Geographic Region - Percentage Breakdown of Revenues for USA,
      Japan, Europe, and Rest of World for Years 2003, 2009 & 2015
      (includes corresponding Graph/Chart)                              II-108

      Table 25: World Recent Past, Current & Future Analysis for
      Nanostructured Materials & Membranes by Geographic Region -
      USA, Japan, Europe, and Rest of World Markets Independently
      Analyzed with Annual Revenue Figures in US$ Million for Years
      2007 through 2015 (includes corresponding Graph/Chart)            II-109

      Table 26: World Historic Review for Nanostructured Materials &
      Membranes by Geographic Region - USA, Japan, Europe, and Rest
      of World Markets Independently Analyzed with Annual Revenue
      Figures in US$ Million for Years 2001 through 2006 (includes
      corresponding Graph/Chart)                                        II-110

      Table 27: World 13-Year Perspective for Nanostructured
      Materials & Membranes by Geographic Region - Percentage
      Breakdown of Revenues for USA, Japan, Europe, and Rest of
      World for Years 2003, 2009 & 2015 (includes corresponding
      Graph/Chart)                                                      II-111

      Table 28: World Recent Past, Current & Future Analysis for
      Nanotubes and Fullerenes by Geographic Region - USA, Japan,
      Europe, and Rest of World Markets Independently Analyzed with
      Annual Revenue Figures in US$ Million for Years 2007 through
      2015 (includes corresponding Graph/Chart)                         II-112

      Table 29: World Historic Review for Nanotubes and Fullerenes
      by Geographic Region - USA, Japan, Europe, and Rest of World
      Markets Independently Analyzed with Annual Revenue Figures in
      US$ Million for Years 2001 through 2006 (includes
      corresponding Graph/Chart)                                        II-113

      Table 30: World 13-Year Perspective for Nanotubes and
      Fullerenes by Geographic Region - Percentage Breakdown of
      Revenues for USA, Japan, Europe, and Rest of World for Years
      2003, 2009 & 2015 (includes corresponding Graph/Chart)            II-114

      Table 31: World Recent Past, Current & Future Analysis for
      Other Nanomaterials by Geographic Region - USA, Japan, Europe,
      and Rest of World Markets Independently Analyzed with Annual
      Revenue Figures in US$ Million for Years 2007 through 2015
      (includes corresponding Graph/Chart)                              II-115

      Table 32: World Historic Review for Other Nanomaterials by
      Geographic Region - USA, Japan, Europe, and Rest of World
      Markets Independently Analyzed with Annual Revenue Figures in
      US$ Million for Years 2001 through 2006 (includes
      corresponding Graph/Chart)                                        II-116

      Table 33: World 13-Year Perspective for Other Nanomaterials by
      Geographic Region - Percentage Breakdown of Revenues for USA,
      Japan, Europe, and Rest of World for Years 2003, 2009 & 2015
      (includes corresponding Graph/Chart)                              II-117

      Table 34: World Recent Past, Current & Future Analysis for
      Nanodevices/Tools by Geographic Region - USA, Japan, Europe,
      and Rest of World Markets Independently Analyzed with Annual
      Revenue Figures in US$ Million for Years 2007 through 2015
      (includes corresponding Graph/Chart)                              II-118

      Table 35: World Historic Review for Nanodevices/Tools by
      Geographic Region - USA, Japan, Europe, and Rest of World
      Markets Independently Analyzed with Annual Revenue Figures in
      US$ Million for Years 2001 through 2006 (includes
      corresponding Graph/Chart                                         II-119

      Table 36: World 13-Year Perspective for Nanodevices/Tools by
      Geographic Region - Percentage Breakdown of Revenues for USA,
      Japan, Europe, and Rest of World for Years 2003, 2009 & 2015
      (includes corresponding Graph/Chart)                              II-120
      Analytics by Application                                          II-121
      Table 37: World Recent Past, Current & Future Analysis for
      Nanobiotechnology by Application - Pharmaceuticals, Medical
      Devices, Medical Research and Others Independently Analyzed
      with Annual Revenue Figures in US$ Million for Years 2007
      through 2015 (includes corresponding Graph/Chart)                 II-121

      Table 38: World 9-Year Perspective for Nanobiotechnology by
      Application - Percentage Breakdown of Revenues for
      Pharmaceuticals, Medical Devices, Medical Research and Others
      for Years 2007, 2009 & 2015 (includes corresponding
      Graph/Chart)                                                      II-122


 III. MARKET

  1. UNITED STATES                                                      III-1
      A.Market Analysis                                                 III-1
        Outlook                                                         III-1
        Industry Overview                                               III-1
        Public Sector Funding                                           III-1
        Major Nanobiotechnology Institutions and Centers                III-2
         The Nanobiotechnology Center (NBTC)                            III-2
          Key technological advances achieved by NBTC in recent years - III-2
          Principal NBTC Partners                                       III-3
         Centre for Biologic Nanotechnology (CBN)                       III-3
         Centre for Biological and Environmental Nanotechnology (CBEN)  III-3
        Regulatory Environment                                          III-4
        Strategic Corporate Developments                                III-4
        Key Players                                                     III-9
      B.Market Analytics                                                III-16
        Table 39: US Recent Past, Current & Future Analysis for
        Nanobiotechnology by Technology Segment - Nanomaterials
        (Solid Inorganic Nanoparticles, Nanocomposites,
        Nanostructured Materials & Membranes, Nanotubes and
        Fullerenes, Other Nanomaterials) and Nanodevices/ Tools
        Markets Independently Analyzed with Annual Revenue Figures
        in US$ Million for Years 2007 through 2015 (includes
        corresponding Graph/Chart)                                      III-16

        Table 40: US Historic Review for Nanobiotechnology by
        Technology Segment - Nanomaterials (Solid Inorganic
        Nanoparticles, Nanocomposites, Nanostructured Materials &
        Membranes, Nanotubes and Fullerenes, Other Nanomaterials)
        and Nanodevices/ Tools Markets Independently Analyzed with
        Annual Revenue Figures in US$ Million for Years 2001 through
        2006 (includes corresponding Graph/Chart)                       III-17

        Table 41: US 13-Year Perspective for Nanobiotechnology by
        Technology Segment -Percentage Breakdown of Revenues for
        Nanomaterials (Solid Inorganic Nanoparticles,
        Nanocomposites, Nanostructured Materials & Membranes,
        Nanotubes and Fullerenes, Other Nanomaterials) and
        Nanodevices/Tools for Years 2003, 2009 & 2015 (includes
        corresponding Graph/Chart)                                      III-18

  2. JAPAN                                                              III-19
      A.Market Analysis                                                 III-19
        Public Sector Funding                                           III-19
        Strategic Corporate Development                                 III-19
      B.Market Analytics                                                III-20
        Table 42: Japanese Recent Past, Current & Future Analysis
        for Nanobiotechnology by Technology Segment - Nanomaterials
        (Solid Inorganic Nanoparticles, Nanocomposites,
        Nanostructured Materials & Membranes, Nanotubes and
        Fullerenes, Other Nanomaterials) and Nanodevices/Tools
        Markets Independently Analyzed with Annual Revenue Figures
        in US$ Million for Years 2007 through 2015 (includes
        corresponding Graph/Chart)                                      III-20

        Table 43: Japanese Historic Review for Nanobiotechnology by
        Technology Segment - Nanomaterials (Solid Inorganic
        Nanoparticles, Nanocomposites, Nanostructured Materials &
        Membranes, Nanotubes and Fullerenes, Other Nanomaterials)
        and Nanodevices/ Tools Markets Independently Analyzed with
        Annual Revenue Figures in US$ Million for Years 2001 through
        2006 (includes corresponding Graph/Chart)                       III-21

        Table 44: Japanese 13-Year Perspective for Nanobiotechnology
        by Technology Segment - Percentage Breakdown of Revenues for
        Nanomaterials (Solid Inorganic Nanoparticles,
        Nanocomposites, Nanostructured Materials &  Membranes,
        Nanotubes and Fullerenes, Other Nanomaterials) and
        Nanodevices/Tools for Years 2003, 2009 & 2015 (includes
        corresponding Graph/Chart)                                      III-22

  3. EUROPE                                                             III-23
      A.Market Analysis                                                 III-23
        Outlook                                                         III-23
        Market Overview                                                 III-23
         European Union Banks Heavily on Nanobiotechnology              III-23
         Nano2Life Network                                              III-24
     Major Nanobiotechnology Networks in Europe As of the Year 2006     III-25
        Public Sector Funding                                           III-25
        Regulatory Environment                                          III-26
         Registration for Novel Nanobiotech Drugs Pose Major
          Bottlenecks                                                   III-26
        Focus on Select Markets                                         III-26
         Germany                                                        III-26
         France                                                         III-27
         United Kingdom                                                 III-27
         Russia                                                         III-27
          Russian Biotech Players Eye Partnerships with Indian
           Counterparts                                                 III-29
         Rest of Europe                                                 III-29
          Ireland                                                       III-29
           Market Overview                                              III-29
           Key Research Institutions/Centers in Nanobiotechnology       III-30
           The Tyndall National Institute                               III-30
           The Centre for Research on Adaptive Nanostructures and
            NanoDevices                                                 III-30
           The National Centre for Sensor Research                      III-30
           The Sami Nasr Institute for Advanced Materials Science       III-30
        Strategic Corporate Developments                                III-31
        Key Players                                                     III-33
      B.Market Analytics                                                III-35
        Table 45: European Recent Past, Current & Future Analysis
        for Nanobiotechnology by Technology Segment - Nanomaterials
        (Solid Inorganic Nanoparticles, Nanocomposites,
        Nanostructured  Materials & Membranes, Nanotubes and
        Fullerenes, Other Nanomaterials) and Nanodevices/Tools
        Markets Independently Analyzed with Annual Revenue Figures
        in US$ Million for Years 2007 through 2015 (includes
        corresponding Graph/Chart)                                      III-35

        Table 46: European Historic Review for Nanobiotechnology by
        Technology Segment - Nanomaterials (Solid Inorganic
        Nanoparticles, Nanocomposites, Nanostructured  Materials &
        Membranes, Nanotubes and Fullerenes, Other Nanomaterials)
        and Nanodevices/ Tools Markets Independently Analyzed
        withAnnual Revenue Figures  in US$ Million for Years 2001
        through 2006 (includes corresponding Graph/Chart)               III-36

        Table 47: European 13-Year Perspective for Nanobiotechnology
        by Technology Segment - Percentage Breakdown of Revenues for
        Nanomaterials (Solid Inorganic Nanoparticles,
        Nanocomposites, Nanostructured Materials & Membranes,
        Nanotubes and Fullerenes, Other Nanomaterials) and
        Nanodevices/Tools for Years 2003 2009 & 2015  (includes
        corresponding Graph/Chart)                                      III-37

  4. REST OF WORLD                                                      III-38
      A.Market Analysis                                                 III-38
        Outlook                                                         III-38
        Public Sector Funding                                           III-38
        Focus on Select Markets                                         III-38
         Australia                                                      III-38
          Market Overview                                               III-38
          Major Institutions                                            III-39
           Commonwealth Scientific and Industrial Research
            Organisation (CSIRO)                                        III-39
         India                                                          III-39
          Market Overview                                               III-39
           Government Takes Big Initiatives to Promote
            Nanobiotechnology                                           III-40
           Agriculture, Livestock Sectors to Warm Up to
            Nanobiotechnology Benefits                                  III-40
         Korea                                                          III-40
         Taiwan                                                         III-41
          Nanotechnology in Medicine - Small Yet Growing Segment in
           Taiwan                                                       III-42
         Iran                                                           III-42
        Strategic Corporate Developments                                III-43
        Key Players                                                     III-45
      B.Market Analytics                                                III-46
        Table 48: Rest of World Recent Past, Current & Future
        Analysis for Nanobiotechnology by Technology Segment -
        Nanomaterials (Solid Inorganic Nanoparticles,
        Nanocomposites, Nanostructured Materials & Membranes,
        Nanotubes and Fullerenes, Other Nanomaterials) and
        Nanodevices/Tools Markets Independently Analyzed with Annual
        Revenue Figures in US$ Million for Years 2007 through 2015
        (includes corresponding Graph/Chart)                            III-46

        Table 49: Rest of World Historic Review for
        Nanobiotechnology by Technology Segment - Nanomaterials
        (Solid Inorganic Nanoparticles, Nanocomposites,
        Nanostructured Materials & Membranes, Nanotubes and
        Fullerenes, Other Nanomaterials) and Nanodevices/ Tools
        Markets Independently Analyzed with Annual Revenue Figures
        in US$ Million for Years 2001 through 2006 (includes
        corresponding Graph/Chart)                                      III-47

        Table 50: Rest of World 13-Year Perspective for
        Nanobiotechnology by Technology Segment - Percentage
        Breakdown of Revenues for Nanomaterials (Solid Inorganic
        Nanoparticles, Nanocomposites, Nanostructured Materials &
        Membranes, Nanotubes and Fullerenes, Other Nanomaterials)
        and Nanodevices/Tools for Years 2003, 2009 & 2015 (includes
        corresponding Graph/Chart)                                      III-48


 IV. COMPETITIVE LANDSCAPE

     Total Companies Profiled: 140 (including Divisions/Subsidiaries - 147)

     ------------------------------------------
     Region/Country                     Players
     ------------------------------------------
     The United States                     90
     Canada                                 4
     Japan                                  2
     Europe                                36
        France                              3
        Germany                             9
        The United Kingdom                 10
        Italy                               1
        Rest of Europe                     13
     Asia-Pacific (Excluding Japan)        10
     Middle-East                            5
     ------------------------------------------